EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV

Hui Wang iD, Yunqin Jiang iD, Shiyun Wang iD, Chanchan Lu iD, Lumin Tang iD, Tingting Gu iD, Shi Shu iD

Acta Pharmaceutica · 2025

DOI: 10.2478/acph-2025-0022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica, 2025. Verfasst von Hui Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1TCM Department, Shanghai Punan Hospital of Pudong New District Shanghai, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Saponins, Triterpenes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder that has become a global health challenge. With the lack of effective FDA-approved treatments, alternative therapies are being explored. Astragaloside IV (AS-IV), a bio-active compound derived from the plant Astragalus membranaceus (Fisch. ex Bunge) (Fabaceae/Leguminosae), native to Inner Mongolia and Siberia, has shown significant therapeutic potential in NAFLD. This review discusses the pharmacological effects and molecular mechanisms of AS-IV, highlighting its role in improving insulin resistance, regulating lipid metabolism, reducing oxidative stress and modulating inflammation. AS-IV acts through key molecular pathways, such as AMPK, Nrf2 and SREBP-1c, to mitigate liver steatosis and inflammation. Additionally, AS-IV influences gut microbiota and bile acid metabolism, contributing to its therapeutic effects. Despite promising results from preclinical studies, clinical data supporting AS-IV’s efficacy in NAFLD treatment are limited. Future research should focus on clinical trials, pharmacokinetics, and the combination of AS-IV with other therapeutic agents to optimise its therapeutic potential and reduce side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseSaponinsTriterpenesHumansAnimalsLipid MetabolismGastrointestinal MicrobiomeOxidative StressInsulin ResistanceAstragalus propinquus

Stichwörter der Autor:innen

NAFLDastragaloside IVgut microbiotainsulin resistancelipid metabolism

Substanzen

SaponinsTriterpenesastragaloside A

Autor:innen und Institutionen

  • 1TCM Department, Shanghai Punan Hospital of Pudong New District Shanghai, China.

ORCID-Profile: Hui Wang, Yunqin Jiang, Shiyun Wang, Chanchan Lu, Lumin Tang, Tingting Gu, Shi Shu

Zitieren

APA

Wang, H., Jiang, Y., Wang, S., Lu, C., Tang, L., Gu, T., & Shu, S. (2025). Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV. Acta Pharmaceutica. https://doi.org/10.2478/acph-2025-0022

Vancouver

Wang H, Jiang Y, Wang S, Lu C, Tang L, Gu T, et al. Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV. Acta Pharmaceutica. 2025. doi:10.2478/acph-2025-0022

BibTeX
@article{Wang2025,
  author = {Wang, Hui and Jiang, Yunqin and Wang, Shiyun and Lu, Chanchan and Tang, Lumin and Gu, Tingting and Shu, Shi},
  title = {Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV},
  journal = {Acta Pharmaceutica},
  year = {2025},
  doi = {10.2478/acph-2025-0022}
}
Kostenlos starten →